Stockscreener 앱 받기
26.21
1.31%
0.34
전일 마감가:
$25.87
열려 있는:
$25.77
하루 거래량:
273.27K
Relative Volume:
0.50
시가총액:
$1.46B
수익:
$2.50M
순이익/손실:
$-131.12M
주가수익비율:
-9.2188
EPS:
-2.8431
순현금흐름:
$-112.73M
1주 성능:
-4.48%
1개월 성능:
-5.07%
6개월 성능:
-43.61%
1년 성능:
+74.27%
1일 변동 폭
$25.66
$26.49
1주일 범위
$25.66
$27.44
52주 변동 폭
$14.27
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
명칭
Maze Therapeutics Inc
전화
(650) 850-5070
주소
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
26.21 | 1.61B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-03-10 | 개시 | Mizuho | Outperform |
| 2025-12-04 | 개시 | Wells Fargo | Overweight |
| 2025-11-14 | 개시 | Raymond James | Outperform |
| 2025-09-02 | 개시 | BTIG Research | Buy |
| 2025-07-23 | 개시 | H.C. Wainwright | Buy |
| 2025-07-08 | 개시 | Wedbush | Outperform |
모두보기
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze (MAZE) Trading: Ends Lower by 4.18% at $28.50 in the Latest Session; Price Context: the $27.07 to $29.93 Range Remains in FocusMESA MA - vinanet.vn
Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - Kalkine
Maze (MAZE) Price: Climbs 0.72% to $29.34 at the Close; Market Levels: Support at $27.87 and Resistance at $30.81 Frame the RangeVolume Oscillator - vinanet.vn
Trv Gp Iv LLC Invests $133.50 Billion in Maze Therapeutics, Inc. $MAZE - MarketBeat
Trv Gp V LLC Buys Shares of 950,800 Maze Therapeutics, Inc. $MAZE - MarketBeat
Alphabet Inc. Acquires New Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics Confirms MZE829 Data Readout for Late 2026 or Early 2027 - Minichart
Maze Therapeutics (MAZE) awards director 36,000 stock options - Stock Titan
Maze Therapeutics (MAZE) awards director 36K stock options - Stock Titan
Maze Therapeutics (NASDAQ: MAZE) director shows no stock or derivative holdings - Stock Titan
Maze Therapeutics (MAZE) director begins reporting with zero shares disclosed - Stock Titan
Maze Therapeutics names Paula Johnson, Sophie Kornowski to board of directors - Bitget
Maze Therapeutics (MAZE) Pulls Back 1.75% as Shares Consolidate Above Key SupportMomentum Factor - vinanet.vn
128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Maze Therapeutics president sells $445,620 in company stock By Investing.com - Investing.com South Africa
Maze Therapeutics president sells $445,620 in company stock - Investing.com
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock - MarketBeat
Maze Therapeutics (MAZE) CMO exercises 16,142 options and sells shares under 10b5-1 plan - Stock Titan
Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $64 - Moomoo
HC Wainwright Has Positive Estimate for MAZE Q3 Earnings - MarketBeat
Maze Therapeutics (MAZE) Edges Higher to $27.66 as Shares Trade Within Established RangeETH Profile - vinanet.vn
Maze Therapeutics adds two directors to board By Investing.com - Investing.com Australia
Maze Therapeutics adds two directors to board - Investing.com
Maze Therapeutics Announces Appointments to Its Board of Directors - The Manila Times
Maze Therapeutics Appoints Paula Johnson and Sophie Kornowski to Board of Directors - Quiver Quantitative
A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $48 to $110 - Moomoo
Maze Therapeutics Inc (MAZE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maze Therapeutics (NASDAQ:MAZE) Earns "Buy" Rating from BTIG Research - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
MAZE SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Maze Therapeutics (MAZE) reports $68.9M loss but ends Q2 with $494.9M in cash - Stock Titan
Maze Therapeutics (NASDAQ:MAZE) Announces Earnings Results - MarketBeat
Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss - marketscreener.com
Maze Therapeutics Reports Q2 Net Loss Of $44.7 Million - Quiver Quantitative
Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses - TradingView
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - The Manila Times
Press Release: Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - Moomoo
Jason Coloma: The FTC Killed Our Sanofi Deal. Six Months Later, We Had a Better One. - finance.biggo.com
Maze Therapeutics (NASDAQ:MAZE) Trading Down 6.8%Should You Sell? - MarketBeat
Maze Therapeutics, Inc. (MAZE): Investor Outlook on a Biotech Stock with 119% Potential Upside - DirectorsTalk Interviews
MAZE Q1 2026 Earnings: Loss Narrower than Expected as No Revenue Is ReportedEarnings Weakness Phase - vinanet.vn
Maze Therapeutics (MAZE) Slides 2.16% to $27.21 as Biotech Volatility PersistsStock Buy Zone - Vinanet
Maze Therapeutics, Inc. (MAZE) CEO Coloma sells 34,501 shares via trusts - Stock Titan
Form 144 Maze Therapeutics For: 3 August By Investing.com - Investing.com Canada
MAZE Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineEarnings Turnaround - vinanet.vn
MAZE PE Ratio & Valuation, Is MAZE Overvalued - Intellectia AI
Maze Therapeutics, Inc. (MAZE): Analyzing A 126% Potential Upside In Biotech Innovation - DirectorsTalk Interviews
Maze Therapeutics (MAZE) Slips 2.91% as Shares Hover Near Key Support at $25.48NAAIM Exposure - dars.gov.et
Maze Therapeutics Inc (MAZE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Maze Therapeutics Inc (MAZE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maze Therapeutics Inc (MAZE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Maze Therapeutics Inc 주식 (MAZE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Courtney Phillips | GC and Corp. Secretary |
Sep 02 '26 |
Sale |
26.47 |
1,981 |
52,432 |
9,019 |
| Courtney Phillips | GC and Corp. Secretary |
Sep 03 '26 |
Sale |
26.01 |
2,012 |
52,334 |
7,007 |
| Dandekar Atul | CSBO |
Sep 02 '26 |
Sale |
26.47 |
3,191 |
84,457 |
35,559 |
| Dandekar Atul | CSBO |
Sep 03 '26 |
Sale |
26.01 |
3,243 |
84,354 |
32,316 |
| Coloma Jason V | Chief Executive Officer |
Sep 02 '26 |
Sale |
26.47 |
11,227 |
297,148 |
38,773 |
| Coloma Jason V | Chief Executive Officer |
Sep 03 '26 |
Sale |
26.01 |
11,411 |
296,807 |
27,362 |
| Bernstein Harold | President, R&D & CMO |
Sep 02 '26 |
Sale |
26.47 |
5,106 |
135,142 |
14,894 |
| Bernstein Harold | President, R&D & CMO |
Sep 03 '26 |
Sale |
26.01 |
5,189 |
134,969 |
9,705 |
| Courtney Phillips | GC and Corp. Secretary |
Sep 01 '26 |
Option Exercise |
0.00 |
11,000 |
0 |
11,000 |
| Dandekar Atul | CSBO |
Sep 01 '26 |
Option Exercise |
0.00 |
12,500 |
0 |
38,750 |
0.86%
0.31%
자본화:
|
볼륨(24시간):